Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Genitourinary Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Genitourinary Other
    Combination Treatment May Help Patients With Peyronie's Disease: Presented at ESSM - (DGDispatch)
    Dynamic MRI Identifies Women With Pelvic Organ Prolapse - (DGNews)
    Propagation of Human Spermatogonial Stem Cells In Vitro - (JAMA)
    Verapamil Injection Eases Pain of Peyronie's Disease: Presented at ESSM - (DGDispatch)
    Patients Prefer Daily Paroxetine for Premature Ejaculation: Presented at ESSM - (DGDispatch)

    News archive

     Recent webcasts/CME - Genitourinary Other
    • Early and Aggressive Management of Treatment-Related Adverse Effects Is Essential for Achieving Optimal Clinical Outcome With Targeted Therapies in Patients With Kidney Cancer
    • Reducing the Burden of Overactive Bladder: A Global Perspective
    • Primary Care Update in Urology
      Urinalysis: A Guide for Pharmacists
      The Treatment of Benign Prostatic Hyperplasia

      Webcasts/CME archive

       Recent cases - Genitourinary Other
        Increased Frequency and Nocturia in a Middle Aged Male May Not Always Be Due to Benign Prostatic Hypertrophy (BPH): A Case Report
        Localized Amyloidosis Presenting with a Penile Mass: A Case Report
        Fetal Bone as a Foreign Body in the Urinary Bladder: A Case Report
        Mycobacterium Avium-Intracellulare Infection Presenting as a Testicular Mass in an Immunocompromised Patient: A Case Report
        Duplex Cryptorchid Testis Presenting as a Strangulated Hernia: A Case Report

        Cases archive
          




        my personal edition > genitourinary other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Dutasteride/Tamsulosin Combo Produces Multiple Benefits in Men With Enlarged Prostates: Presented at EAU

        By Jill Stein

        MILAN, Italy -- March 27, 2008 -- Combination treatment with the dual 5 alpha-reductase inhibitor dutasteride and the alpha blocker tamsulosin results in continuous symptomatic improvement in men with benign prostatic hyperplasia (BPH) and in patient-reported quality of life, investigators said here at the 23rd Annual European Association of Urology (EAU) Congress.

        Jack Barkin, MD, Assistant Professor of Surgery, University of Toronto, Toronto, Ontario, Canada, and colleagues randomised 4,800 men with moderate to severe BPH to receive the dutasteride and tamsulosin combination, dutasteride monotherapy, or tamsulosin monotherapy after a 4-week placebo run-in period.

        Findings from a preplanned 2-year analysis of the 4-year Combination of Avodart and Tamsulosin trial revealed that combination therapy resulted in significantly greater improvements in symptoms and flow rate than either drug alone, said Dr. Barkin.

        Secondary endpoints in the 2-year analysis included the BPH Impact Index (BII) and question 8 of the International Prostate Symptom Scale (IPSS Q8), which is a BPH-related health status/motivational scale.

        Analysis of secondary endpoints found that at month 24, improvements in BII score and IPSS Q8 score from baseline were significantly greater with combination therapy compared with each monotherapy regimen (P < .001).

        Improvement in BII score from baseline was significantly greater with combination therapy from month 3 versus dutasteride and from month 9 versus tamsulosin (P < .01).

        Combination therapy was associated with a significant improvement from baseline in IPSS Q8 score from month 3 versus dutasteride and from month 12 versus tamsulosin (P < .001).

        Results also showed a significant benefit of combination therapy over each monotherapy regimen for treatment satisfaction, which was examined using a questionnaire specifically developed for use and validation in COMBAT to assess patient treatment satisfaction (P < .001).

        Dr. Barkin said this trial is the first to demonstrate the significant superiority of the combination of a 5 alpha reductase inhibitor and alpha blocker over each drug alone in improving patient-reported quality of life.

        BPH is a progressive disease which has a considerable negative impact on patient quality of life. Bother and interference with daily activities are the main drivers for BPH patients to seek healthcare. The condition affects 50% of men aged more than 50 years, and more than 90% of men aged more than 80 years.

        Funding for this study was provided by GlaxoSmithKline.

        [Presentation title: Improvements in Patient-Reported Quality of Life With Dutasteride, Tamsulosin and the Combination: Two-Year Results From the Combination of Avodart and Tamsulosin (CombAT) Trial. Abstract 99]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send